

8 November 2023

## RESULTS OF ANNUAL GENERAL MEETING

Botanix Pharmaceuticals Ltd (ASX:BOT) (“Botanix” or the “Company”) wishes to advise pursuant to Listing Rule 3.13.2 that all resolutions presented at the 2023 Annual General Meeting of Shareholders held today were carried by a poll.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

Release authorised by the Board of Directors.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofpironium Bromide for the treatment of primary axillary hyperhidrosis, through FDA approval. A mid-cycle review for the product was successfully completed by FDA in 1Q 2023 and approval is targeted for late 3Q CY 2023. Sofpironium Bromide is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

#### General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)

# Disclosure of Proxy Votes

## Botanix Pharmaceuticals Limited

Annual General Meeting

Wednesday, 08 November 2023



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Non-Binding Resolution to Adopt Remuneration Report	P	248,321,085	222,375,025 89.55%	24,013,909 9.67%	412,572	1,932,151 0.78%	230,092,245 89.60%	26,713,909 10.40%	412,572	Passed
2 Re-election of Mr Vincent Ippolito as a Director	P	358,345,058	352,695,654 98.42%	3,683,933 1.03%	260,200	1,965,471 0.55%	363,801,078 99.00%	3,683,933 1.00%	260,200	Passed
3 Re-election of Mr Matthew Callahan as a Director	P	358,345,058	354,530,654 98.94%	1,848,933 0.52%	260,200	1,965,471 0.55%	365,636,078 99.50%	1,848,933 0.50%	260,200	Passed
4 Approval of Additional 10% Placement Capacity	P	357,611,954	352,690,759 98.62%	2,933,724 0.82%	993,304	1,987,471 0.56%	361,118,183 99.19%	2,933,724 0.81%	3,693,304	Passed
5 Approval of Potential Termination Benefits to Dr Howard McKibbin (or his nominee(s))	P	246,813,657	226,808,395 91.89%	18,031,295 7.31%	16,852,957	1,973,967 0.80%	234,567,431 91.88%	20,731,295 8.12%	16,852,957	Passed
6 Approval of Employee Awards Plan	P	247,019,341	239,758,412 97.06%	5,273,904 2.14%	16,647,273	1,987,025 0.80%	247,530,506 96.88%	7,973,904 3.12%	17,302,157	Passed

